US FDA COMPLETES INSPECTION OF JUBILANT INGREVIA'S BHARUCH FACILITY WITH ZERO OBSERVATIONS

Jubilant Ingrevia announced, in an exchange filing on June 27, that its unit-1 manufacturing facility located in Bharuch, Gujarat, has received an establishment inspection report (EIR) from the FDA without any observations. "Our manufacturing site, Unit-1, intended for the manufacturing of Nutraceuticals & Dietary- Active ingredients for Human consumption in a GMP compliant facility located at Bharuch, Gujarat India has successfully undergone its maiden USFDA inspection with the outcome of zero 483 inspectional observations," CEO & Managing Director Deepak Jain said.

The inspection, conducted in April by FDA officials, aimed to assess compliance with Good Manufacturing Practices (GMP) and other regulatory standards crucial for the production of substances intended for human consumption.

"This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the Company’s strategic capex initiative, shall position Jubilant Ingrevia further to capitalize and mark Company’s foray into regulated market to cater the growing business requirements in the Nutraceuticals, Dietary Active Ingredients, Cosmetic Grade Applications – Active Ingredients, Drug Intermediates, CDMO products intended for industry application and human consumption," the company said.

The shares of Jubilant Ingrevia settled 3.4% lower at ₹516.80 apiece today.

Also Read: Dr Reddy's Laboratories to acquire Nicotinell from Haleon — here’s why analysts are divided

2024-06-27T13:41:55Z dg43tfdfdgfd